Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

We Arc Krystal Biotech's Vyjuvek: A Topical Triumph Driving Gains Krystal Biotech's (NASDAQ:KRYS) stock has risen another 25.6% since my previous "strong buy" recommendation in February. 100 Analyst's Rating History on KRYS ● Strong Buy ● Buy ● Hold ● Soll ● Strong Sell Jan '24 Oct "23 Apr "24 Jul '24 50 250 200 150 Seeking Alpha Back then, I wrote about their Q4 earnings report, which showed strong sales and high patient compliance for Vyjuvek, Krystal Biotech's dystrophic epidermolysis bullosa (DEB) topic ...